MAD0004J08

BIOLOGICAL2 trials

Sponsors

Toscana Life Sciences Sviluppo s.r.l.

Conditions

COVID-19 Virus DiseaseCovid19

Phase 1

Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.

CompletedNCT04932850

Toscana Life Sciences Sviluppo s.r.l.COVID-19 Virus Disease

Start: 2021-03-01End: 2021-10-20Updated: 2022-04-27

Phase 2

Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.

Toscana Life Sciences Sviluppo s.r.l.Covid19

Start: 2021-06-06End: 2022-08-31Target: 800Updated: 2022-02-03

Related Papers

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection

Nature Communications2022-04-2711 citations